Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07618546 | A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | not yet recruiting | N/A | 208 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07618949 | Standardized Patient Education in Pituitary Surgery | not yet recruiting | N/A | 102 | Uludag UniversityOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | not yet recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07605702 | The Canopy Cancer Collective Clinical Registry Protocol | not yet recruiting | — | 100,000 | Canopy Cancer Collective, LLCNETWORK | 1 | May 26, 2026 | clinicaltrials |
| NCT07602101 | Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | not yet recruiting | Phase 2 | 33 | RenJi HospitalOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy(V-COSMOS) | not yet recruiting | — | 160 | Cukurova UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593040 | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma(Moonlanding) | not yet recruiting | Phase 2 | 150 | Vall d'Hebron Institute of OncologyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07600346 | A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery | not yet recruiting | — | 105 | The First Hospital of Jilin UniversityOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07592819 | A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)(PRODIGE 104 B) | not yet recruiting | N/A | 367 | Institut Paoli-CalmettesOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT07594548 | Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | not yet recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07590583 | Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial | not yet recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584018 | The DoHAICs Study Expansion Phase | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07584317 | AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601) | not yet recruiting | — | 1,170 | Gao-jun TengOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581288 | Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression(MIRA) | not yet recruiting | — | 50 | University of British ColumbiaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07582419 | Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions(HDL-CEUS-MRI) | not yet recruiting | — | 1,424 | The First Hospital of Jilin UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07568756 | Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation | not yet recruiting | Phase 2 | 60 | University of California, IrvineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06899347 | The Role of Prophylactic Central Compartment Neck Dissection in the Management of 2 to 4 cm Papillary Thyroid Carcinoma(PRO-COMAND) | not yet recruiting | N/A | 392 | Leonardo RossiOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 16 | Amit MahipalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07568366 | AI in Endoscopic Transsphenoidal Surgery | not yet recruiting | Early Phase 1 | 30 | University College, LondonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07568457 | Social Determinants of Health HCC Trial | not yet recruiting | N/A | 75 | University of Southern CaliforniaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07565415 | Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | not yet recruiting | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07561463 | Sacituzumab Tirumotecan for Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07556835 | Outcomes After Liver and Biliary Resection at a High-Volume Center(BILIVER) | not yet recruiting | — | 1,000 | Azienda USL Toscana CentroOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07543783 | Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial | not yet recruiting | Phase 2 | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | not yet recruiting | Early Phase 1 | 156 | Ningbo No.2 HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07547033 | Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy(EQUINOXE) | not yet recruiting | N/A | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07543510 | Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07544121 | Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis | not yet recruiting | N/A | 1,034 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07544134 | Areola Preservation in NSM With Nipple Involvement(APRESERVE-1) | not yet recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06655142 | OSCAR II STUDY - The ONCObind CTC Removal Study | not yet recruiting | N/A | 120 | ExThera Medical CorporationINDUSTRY | 0 | Apr 17, 2026 | clinicaltrials |
| NCT07536412 | Decision Aid Efficacy in Low Risk Thyroid Cancer | not yet recruiting | N/A | 34 | University of Maryland, BaltimoreOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537777 | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy | not yet recruiting | Phase 2 | 29 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | not yet recruiting | Phase 3 | 400 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537959 | Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases | not yet recruiting | N/A | 280 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2026source: clinicaltrials